JP7529959B2 - Skin Composition - Google Patents
Skin Composition Download PDFInfo
- Publication number
- JP7529959B2 JP7529959B2 JP2019219007A JP2019219007A JP7529959B2 JP 7529959 B2 JP7529959 B2 JP 7529959B2 JP 2019219007 A JP2019219007 A JP 2019219007A JP 2019219007 A JP2019219007 A JP 2019219007A JP 7529959 B2 JP7529959 B2 JP 7529959B2
- Authority
- JP
- Japan
- Prior art keywords
- shinorine
- acid
- composition
- examples
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、しわ改善効果及び美白効果を有する皮膚用組成物に関する。 The present invention relates to a skin composition that has wrinkle improving and whitening effects.
シノリンは天然の希少アミノ酸群であるマイコスポリン様アミノ酸(MAAs)の一種であり、天然に存在する最も紫外線吸収能の高い物質の一つとして知られている。特に皮膚の老化であるシミ、シワ、たるみの原因であるUVA領域の吸収能が高い。特に既存の紫外線吸収剤では十分にカバーしきれない領域であるUV-A2領域(320~340nm)に極大吸収を示す。自然界においてシノリンは水生生物である紅藻類やサンゴ、シアノバクテリアなどに存在する。 Shinorine is a type of mycosporine-like amino acids (MAAs), a group of rare natural amino acids, and is known to be one of the naturally occurring substances with the highest ultraviolet absorbing capacity. It has particularly high absorption capacity in the UVA region, which is the cause of skin aging such as spots, wrinkles, and sagging. It has a maximum absorption in the UV-A2 region (320-340 nm), a region that cannot be fully covered by existing ultraviolet absorbents. In nature, shinorine is found in aquatic organisms such as red algae, coral, and cyanobacteria.
シノリンは水溶性物質であり、医薬部外品、化粧品への処方は大きなメリットである。シノリンを含有するMAAsは紫外線による皮膚中のエラスチン、コラーゲンのダメージを抑える働きがある。さらに、ヒアルロン酸の生成を促進する効果も示唆されており、アンチエイジング効果が高い物質として期待されている。 Shinorine is a water-soluble substance, which has great merit when formulated into quasi-drugs and cosmetics. MAAs containing shinorine work to reduce damage to elastin and collagen in the skin caused by ultraviolet rays. It has also been suggested to promote the production of hyaluronic acid, making it a promising substance with strong anti-aging effects.
シノリンを医薬部外品や化粧品材料として用いることは公知である(特許文献1)。また、シノリンの製造方法も公知である(特許文献2)。 It is known that shinorine is used as a quasi-drug or cosmetic ingredient (Patent Document 1). A method for producing shinorine is also known (Patent Document 2).
本発明の目的は、優れたしわ改善効果及び美白効果を有する皮膚用組成物を提供することである。 The object of the present invention is to provide a skin composition that has excellent wrinkle improving and whitening effects.
本願発明者らは鋭意研究の結果、マイクロスポリン様アミノ酸と抗酸化剤を共存させることにより、優れたしわ改善効果及び美白効果が発揮されることを見出し、本発明を完成した。 As a result of extensive research, the inventors of the present invention discovered that the coexistence of microsporin-like amino acids and antioxidants provides excellent wrinkle-improving and whitening effects, and thus completed the present invention.
すなわち、本発明は以下のものを提供する。
(1) (i) シノリンと、
(ii) トラネキサム酸、コウジ酸、レチノール、アスコルビン酸、コエンザイムQ10、ハイドロキノン、トコフェロール及びβ-カロテンから成る群より選ばれる少なくとも1種の抗酸化剤と
を含む、コラーゲン産生促進剤。
(2) 前記シノリンを含有する海藻エキスを含む、(1)記載のコラーゲン産生促進剤。
That is, the present invention provides the following.
(1) (i) Shinorine;
(ii) A collagen production promoter comprising at least one antioxidant selected from the group consisting of tranexamic acid, kojic acid, retinol, ascorbic acid, coenzyme Q10, hydroquinone, tocopherol and β-carotene.
(2) The collagen production promoter according to (1), comprising a seaweed extract containing shinorine.
本発明により、優れたしわ改善効果及び美白効果を有する皮膚用組成物が提供された。 The present invention provides a skin composition that has excellent wrinkle improving and whitening effects.
本発明の皮膚用組成物は、化粧品であってもよいし、美白化粧料と抗シワ化粧料のような医薬部外品であってもよい。これらの形態としては、化粧水、乳液、クリーム、美容液、UV、BBクリーム、化粧下地などが挙げられるがこれらに限定されるものではない。 The skin composition of the present invention may be a cosmetic product or a quasi-drug product such as a whitening cosmetic product or an anti-wrinkle cosmetic product. Examples of the form of the skin composition include, but are not limited to, a lotion, milky lotion, cream, beauty serum, UV cream, BB cream, makeup base, etc.
本発明の皮膚用組成物中に必須成分として含まれるマイクロスポリン様アミノ酸自体及びその製造方法は公知であり、市販もされているので、市販品を用いることができる。マイクロスポリン様アミノ酸としては、シノリン、パリシン、ポルフィラー334、マイコスポリングリシン等が挙げられる。これらのうち、シノリンが好ましい。これらのマイクロスポリン様アミノ酸は、単独で含まれていても複数種類のものが含まれていてもよい。また、これらのマイクロスポリン様アミノ酸は、海藻エキス(緑藻エキス、褐藻エキス、紅藻エキス)中に含まれるので、各マイクロスポリン様アミノ酸を精製せずに海藻エキスを組成物中に含めてもよい。 The microsporin-like amino acids contained as essential components in the skin composition of the present invention and the method for producing them are known and commercially available, so commercially available products can be used. Examples of microsporin-like amino acids include shinorine, paricine, porphyra 334, mycosporine glycine, and the like. Of these, shinorine is preferred. These microsporin-like amino acids may be contained alone or in combination. In addition, these microsporin-like amino acids are contained in seaweed extracts (green algae extracts, brown algae extracts, red algae extracts), so the seaweed extracts may be included in the composition without purifying each microsporin-like amino acid.
組成物中のマイクロスポリン様アミノ酸の配合量(複数種類のものが含まれる場合にはその合計量)は、特に限定されず、しわ改善効果及び美白効果を発揮する範囲内で適宜設定されるが、組成物全量1mL当り通常、0.01μg~100μg程度、好ましくは、0.05μg~50μg程度、さらに好ましくは0.1μg~5.0μg程度である。 The amount of microsporin-like amino acid in the composition (the total amount when multiple types are included) is not particularly limited and is appropriately set within the range that exhibits wrinkle improvement and whitening effects, but is usually about 0.01 μg to 100 μg, preferably about 0.05 μg to 50 μg, and more preferably about 0.1 μg to 5.0 μg per 1 mL of the total composition.
本発明の皮膚用組成物中に必須成分として含まれる抗酸化剤としては、皮膚に適用可能な抗酸化剤であれば特に限定されず、化粧品又は医薬部外品の成分として用いることが知られている各種抗酸化剤を用いることができる。このような抗酸化剤の例として、トラネキサム酸、コウジ酸、レチノール、コエンザイムQ10、ハイドロキノン、トコフェロール、アスコルビン酸、β-カロテン、BHT、亜硫酸ナトリウム及びメタ重亜硫酸ナトリウム、並びにこれらの誘導体等を挙げることができるがこれらに限定されるものではない。これらのうち、トラネキサム酸、コウジ酸、レチノール、コエンザイムQ10、ハイドロキノン、トコフェロール、アスコルビン酸、β-カロテンが好ましい。抗酸化剤は、単独でも用いることができるし、2種以上を組み合わせて用いることもできる。組成物中の抗酸化剤の配合量(2種以上の抗酸化剤を用いる場合にはその合計量)は、特に限定されず、しわ改善効果及び美白効果を発揮する範囲内で適宜設定されるが、組成物全量1mL当り通常、0.01μg~100μg質量%程度、好ましくは、0.05μg~50μg程度、さらに好ましくは0.1μg~10μg程度である。 The antioxidant contained as an essential component in the skin composition of the present invention is not particularly limited as long as it is an antioxidant that can be applied to the skin, and various antioxidants known to be used as components of cosmetics or quasi-drugs can be used. Examples of such antioxidants include, but are not limited to, tranexamic acid, kojic acid, retinol, coenzyme Q10, hydroquinone, tocopherol, ascorbic acid, β-carotene, BHT, sodium sulfite, sodium metabisulfite, and derivatives thereof. Of these, tranexamic acid, kojic acid, retinol, coenzyme Q10, hydroquinone, tocopherol, ascorbic acid, and β-carotene are preferred. The antioxidants can be used alone or in combination of two or more. The amount of antioxidant in the composition (the total amount when two or more antioxidants are used) is not particularly limited and is appropriately set within the range that exhibits wrinkle improvement and whitening effects, but is usually about 0.01 μg to 100 μg mass% per 1 mL of the total composition, preferably about 0.05 μg to 50 μg, and more preferably about 0.1 μg to 10 μg.
上記抗酸化剤のうち、トラネキサム酸、コウジ酸、レチノール、コエンザイムQ10、ハイドロキノン、トコフェロール、アスコルビン酸及びβ-カロテンから成る群より選ばれる少なくとも1種を配合することにより、特に優れたしわ改善効果が得られる。しわ改善効果は、下記実施例に具体的に記載するように、ヒアルロン酸産生促進効果又はコラーゲン産生促進効果により評価することができる。また、上記抗酸化剤のうち、コウジ酸、ハイドロキノン、アスコルビン酸及びトラネキサム酸から成る群より選ばれる少なくとも1種を配合することにより、特に優れた美白効果が得られる。美白効果は、下記実施例に具体的に記載するように、チロシナーゼ活性阻害効果により評価することができる。 A particularly excellent wrinkle-improving effect can be obtained by blending at least one selected from the group consisting of tranexamic acid, kojic acid, retinol, coenzyme Q10, hydroquinone, tocopherol, ascorbic acid, and β-carotene among the above antioxidants. The wrinkle-improving effect can be evaluated by the effect of promoting hyaluronic acid production or the effect of promoting collagen production, as specifically described in the Examples below. Furthermore, a particularly excellent whitening effect can be obtained by blending at least one selected from the group consisting of kojic acid, hydroquinone, ascorbic acid, and tranexamic acid among the above antioxidants. The whitening effect can be evaluated by the effect of inhibiting tyrosinase activity, as specifically described in the Examples below.
本願発明の皮膚用組成物は、しわ改善効果及び美白効果を発揮するので、しわ改善剤又は美白化粧料として用いることができる。もちろん、しわ改善効果と美白効果を同時に発揮する化粧料組成物としても用いることができる。この場合には、しわ改善効果及び美白効果の両方に優れた抗酸化剤、すなわち、コウジ酸、ハイドロキノン、アスコルビン酸及びトラネキサム酸から成る群より選ばれる少なくとも1種を用いることが好ましい。 The skin composition of the present invention exerts wrinkle-improving and whitening effects, and can therefore be used as a wrinkle-improving agent or whitening cosmetic. Of course, it can also be used as a cosmetic composition that exerts both wrinkle-improving and whitening effects at the same time. In this case, it is preferable to use an antioxidant that is excellent in both wrinkle-improving and whitening effects, that is, at least one selected from the group consisting of kojic acid, hydroquinone, ascorbic acid, and tranexamic acid.
本発明の化粧料組成物は、上記各成分を溶媒中に含むものでよく、溶媒としては水が好ましい(少量(5質量%以下程度)のエタノールを含んでいてもよい)。溶媒が水の場合、化粧水の形態となる。化粧水の場合、各成分を水に入れ、ホモジナイズすることにより、本発明の化粧料を製造することができる。また、本発明の化粧料組成物は、化粧水の形態に限らず、周知の方法によりクリームやゲルの形態とすることもできる。クリームの形態にする場合、周知のとおり、モノステアリン酸グリセリル, モノステアリン酸ポリエチレングリコール、ポリソルベート、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンラウリルエーテル類等の添加剤を、例えば0.10質量%~20.00質量%程度添加することによりクリームの形態にすることができる。また、ゲルの形態にする場合、周知のとおり、カルボキシビニルポリマー、(アクリレーツ/アクリル酸アルキル )クロスポリマー、ポリアクリルアミド、ゼラチン、ヒドロキシエチルセルロース、キサンタンガム、ジラウロイルグルタミン酸リシンNa、アクリレーツクロスポリマー、ベントナイト類、ヘクトライト類、(アクリレーツ/イタコン酸ステアレス-20)コポリマー、ヒドロキシプロピルデンプンリン酸、ポリグルタミン酸Na、ポリビニルピロリドン、(ビニルピロリドン/VA)コポリマー、ステアロキシヒドロキシプロピルメチルセルロース、ポリビニルアルコール、シロキクラゲ多糖体等の添加剤を、例えば0.01質量%~10.00質量%程度添加することによりゲルの形態にすることができる。 The cosmetic composition of the present invention may contain the above-mentioned components in a solvent, and the solvent is preferably water (a small amount (about 5% by mass or less) of ethanol may be contained). When the solvent is water, the cosmetic composition is in the form of a lotion. In the case of a lotion, the cosmetic composition of the present invention can be produced by adding each component to water and homogenizing it. The cosmetic composition of the present invention is not limited to the form of a lotion, and can also be in the form of a cream or gel by a well-known method. When the cosmetic composition is in the form of a cream, as is well known, it can be made into the form of a cream by adding additives such as glyceryl monostearate, polyethylene glycol monostearate, polysorbate, polyoxyethylene hydrogenated castor oil, polyoxyethylene lauryl ethers, for example, in an amount of about 0.10% by mass to 20.00% by mass. Furthermore, when forming a gel, as is well known, additives such as carboxyvinyl polymers, (acrylates/alkyl acrylate) crosspolymers, polyacrylamide, gelatin, hydroxyethyl cellulose, xanthan gum, sodium dilauroyl glutamate lysine, acrylates crosspolymers, bentonites, hectorites, (acrylates/steareth-20 itaconate) copolymers, hydroxypropyl starch phosphate, sodium polyglutamate, polyvinylpyrrolidone, (vinylpyrrolidone/VA) copolymers, stearoxyhydroxypropylmethylcellulose, polyvinyl alcohol, and tremella fuciformis polysaccharides can be added in an amount of, for example, about 0.01% to 10.00% by mass to form a gel.
本発明の化粧料組成物は、上記した必須成分に加え、化粧料に用いられている各種の添加剤をさらに含んでいてもよい。このような添加剤としては、抗菌剤、保湿剤、抗炎症剤等を挙げることができるがこれらに限定されるものではない。抗菌剤としては、パラベン類、フェノキシエタノール、ペンチレングリコール、カプリン酸グリセリル、イソプロピルメチルフェノール、O-シメン-5-オール、オクタンジオール等を例示することができる。保湿剤としては、グリセリン、ブチレングリコール、ヒアルロン酸Na、セラミド類、コンドロイチン硫酸Na、コラーゲン、カンゾウ葉エキス、アマチャヅル葉エキス、ゲットウ葉エキス等を例示することができる。抗炎症剤としては、グリチルリチン酸ジカリウム、アラントイン、オウゴンエキス、オタネニンジンエキス、カミツレエキス、カンゾウフラボノイド等を例示することができる。 The cosmetic composition of the present invention may further contain various additives used in cosmetics in addition to the essential components described above. Examples of such additives include, but are not limited to, antibacterial agents, moisturizing agents, and anti-inflammatory agents. Examples of antibacterial agents include parabens, phenoxyethanol, pentylene glycol, glyceryl caprate, isopropylmethylphenol, O-cymen-5-ol, and octanediol. Examples of moisturizing agents include glycerin, butylene glycol, sodium hyaluronate, ceramides, sodium chondroitin sulfate, collagen, licorice leaf extract, Gynostemma pentaphyllum leaf extract, and Alpinia speciosa leaf extract. Examples of anti-inflammatory agents include dipotassium glycyrrhizinate, allantoin, Scutellaria baicalensis extract, Panax ginseng extract, chamomile extract, and licorice flavonoids.
以下、本発明を実施例に基づき具体的に説明する。もっとも、本発明は下記実施例に限定されるものではない。 The present invention will be specifically described below based on examples. However, the present invention is not limited to the following examples.
実施例1~18、比較例1~19 ヒアルロン酸産生促進効果(しわ改善効果)試験
精製水1mL中にシノリン1μgと、表1に示す各種抗酸化剤を表1に示す量だけ溶解した組成物を調製した。比較のため、精製水1mL中にシノリンのみを1μg溶解した組成物(比較例1)及び精製水1mL中に表1に示す抗酸化剤のみを溶解した組成物(比較例2~19)を調製した。また、陰性対照として精製水、陽性対照としてN-アセチルグルコサミン(GlcNac)を用いた。
Examples 1 to 18, Comparative Examples 1 to 19 Hyaluronic acid production promoting effect (wrinkle improvement effect) test Compositions were prepared by dissolving 1 μg of shinorine and various antioxidants shown in Table 1 in the amounts shown in Table 1 in 1 mL of purified water. For comparison, a composition was prepared by dissolving 1 μg of shinorine alone in 1 mL of purified water (Comparative Example 1) and a composition was prepared by dissolving only an antioxidant shown in Table 1 in 1 mL of purified water (Comparative Examples 2 to 19). Purified water was used as a negative control, and N-acetylglucosamine (GlcNac) was used as a positive control.
ヒアルロン酸産生促進効果は次のようにして評価した。24穴プレートの各ウェルに、ヒト皮膚繊維芽細胞(クラボウ社製品)を5×10000細胞/ml入れた。5%FCS-MEM (Fetal Calf SerumーMinimum Essential amino acids Media)を用い37℃、5%二酸化炭素形状維持のまま72時間培養した。その後、0.5% FCS-MEMに交換し、試料を最終濃度10μg/mlに添加した。陽性対象のN-アセチルグルコサミンは最終濃度0.1mMol添加した。添加から24時間後の各培養液上清中のヒアルロン酸量を定量した。ヒアルロン酸結合タンパク質(HABP)およびビオチン標識HABPを用いた結合タンパクサンドウィッチ法を用いた。マイクロプレートリーダーにて 450nmの吸光度測定を行った。ヒアルロン酸産生促進率は、陰性対象のヒアルロン酸量を100として算出した。結果を下記表2に示す。 The hyaluronic acid production promotion effect was evaluated as follows. Human dermal fibroblasts (Kurabo Industries, Ltd.) were placed in each well of a 24-well plate at 5 x 10,000 cells/ml. They were cultured for 72 hours at 37°C in 5% carbon dioxide using 5% FCS-MEM (Fetal Calf Serum-Minimum Essential Amino Acids Media). After that, the medium was replaced with 0.5% FCS-MEM, and the sample was added to a final concentration of 10 μg/ml. N-acetylglucosamine, the positive control, was added to a final concentration of 0.1 mMol. The amount of hyaluronic acid in each culture supernatant 24 hours after addition was quantified. The binding protein sandwich method using hyaluronic acid binding protein (HABP) and biotin-labeled HABP was used. Absorbance was measured at 450 nm using a microplate reader. The hyaluronic acid production promotion rate was calculated by setting the amount of hyaluronic acid in the negative control as 100. The results are shown in Table 2 below.
表1に示されるように、各実施例におけるヒアルロン酸量は、シノリンのみを含む場合(比較例1)と対応する各濃度の各抗酸化剤のみを含む場合(比較例2~19)の和よりも大きくなっており、シノリンと各種抗酸化剤との併用により、ヒアルロン酸の産生量について相乗効果が発揮されることが明らかになった。 As shown in Table 1, the amount of hyaluronic acid in each Example was greater than the sum of the amount when only shinorine was included (Comparative Example 1) and the amount when only the corresponding concentration of each antioxidant was included (Comparative Examples 2 to 19). This demonstrates that the combined use of shinorine and various antioxidants produces a synergistic effect on the amount of hyaluronic acid produced.
実施例19~21、比較例20~23 美白効果試験
シノリン0.5μgと、下記表2に示す各抗酸化剤0.5μgとを1mLの精製水に溶解した(実施例19~21)。比較のため、シノリン0.5μgを1mLの精製水に溶解した(比較例20)。また、各抗酸化剤0.5μgを1mLの精製水に溶解した(比較例20~23)。
Examples 19-21, Comparative Examples 20-23 Skin Whitening Effect Test 0.5 μg of shinorine and 0.5 μg of each antioxidant shown in Table 2 below were dissolved in 1 mL of purified water (Examples 19-21). For comparison, 0.5 μg of shinorine was dissolved in 1 mL of purified water (Comparative Example 20). In addition, 0.5 μg of each antioxidant was dissolved in 1 mL of purified water (Comparative Examples 20-23).
チロシナーゼは、メラニン生成過程において、チロシンからL-DOPAへの水酸化反応、及びL-DOPAからドーパキノンへの酸化反応を触媒しており、生体内でチロシンからのメラニン生合成に直接影響を及ぼしている。チロシナーゼの阻害はメラニン生成阻害につながる。本発明の組成物がチロシナーゼ活性を阻害する効果を調べた。 In the melanin production process, tyrosinase catalyzes the hydroxylation reaction of tyrosine to L-DOPA and the oxidation reaction of L-DOPA to dopaquinone, and directly affects the biosynthesis of melanin from tyrosine in the body. Inhibition of tyrosinase leads to inhibition of melanin production. The effect of the composition of the present invention in inhibiting tyrosinase activity was investigated.
0.1Mリン酸バッファー(PH6.5)600μlに、2.5mML-チロシン水溶液を333μl加えた。両試薬を25℃でインキュベートした。ついで33μlの試料溶液(DMSO溶液)を加えて撹拌し、33μlのチロシナーゼ水溶液(1380unit/ml)を加えて酵素反応を開始した。測定は分光光度計を用いる。測定機内は25℃に保たれるよう設定した。活性の評価はチロシナーゼにより合成されるメラニンの吸光度変化(405nm)を指標とした。結果を下記表2に示す。 333 μl of 2.5 mM L-tyrosine aqueous solution was added to 600 μl of 0.1 M phosphate buffer (pH 6.5). Both reagents were incubated at 25°C. Next, 33 μl of sample solution (DMSO solution) was added and stirred, and 33 μl of tyrosinase aqueous solution (1380 units/ml) was added to start the enzyme reaction. A spectrophotometer was used for measurement. The inside of the measuring device was set to be kept at 25°C. Activity was evaluated using the change in absorbance (405 nm) of melanin synthesized by tyrosinase as an indicator. The results are shown in Table 2 below.
表2に示されるように、各実施例におけるチロシナーゼ阻害%は、シノリンのみを含む場合(比較例20)と対応する各濃度の各抗酸化剤のみを含む場合(比較例21~23)の和よりも大きくなっており、シノリンと各種抗酸化剤との併用により、チロシナーゼの阻害活性について相乗効果が発揮されることが明らかになった。 As shown in Table 2, the tyrosinase inhibition percentage in each Example was greater than the sum of the percentages when only shinorine was included (Comparative Example 20) and when only the corresponding concentrations of each antioxidant were included (Comparative Examples 21 to 23), demonstrating that the combined use of shinorine with various antioxidants exerts a synergistic effect on the inhibitory activity of tyrosinase.
実施例23~62、比較例24~64 コラーゲン産生促進効果(しわ改善効果)試験
正常ヒト線維芽細胞に被験物質を48時間暴露したのち、染色液(シリウスレッド及びファストグリーン)を用いて常法により細胞内のコラーゲン及び非コラーゲンタンパク質を染色し、細胞内のコラーゲン量を定量する試験を行った。
Examples 23 to 62, Comparative Examples 24 to 64 Collagen Production Promotion Effect (Wrinkle Improvement Effect) Test After normal human fibroblasts were exposed to the test substances for 48 hours, intracellular collagen and non-collagen proteins were stained by a standard method using staining solutions (Sirius Red and Fast Green), and a test was performed to quantify the amount of collagen in the cells.
予備試験として、24時間培養した人線維芽細胞に被験物質を48時間暴露(1.0mL)し、MTT法により細胞生存率を求め、細胞に影響を与えない被験物質濃度を確認した。被験物質1.0mL中に含まれる物質は、エタノール50%、被験物質総量、残りは水である。 As a preliminary test, human fibroblasts cultured for 24 hours were exposed to the test substance (1.0 mL) for 48 hours, and the cell viability was determined using the MTT method to confirm the test substance concentration that did not affect the cells. The substances contained in 1.0 mL of the test substance were 50% ethanol, the total amount of the test substance, and the remainder was water.
本試験では、ヒト線維芽細胞を試験用プレートで24時間培養し、被験物質1.0mLを混合した培地に交換し、48時間培養した。細胞をシリウスレッド及びファストグリーンで染色し、常法によりコラーゲン及びタンパク質を抽出した。吸光度(570nm)を測定し、総タンパク質量当たりのコラーゲン量を求めた。各例のサンプル数は3であった。また、陽性対照としては、3-O-エチルアスコルビン酸を用いた(データ示さず)。結果を下記表3に示す。 In this test, human fibroblasts were cultured in a test plate for 24 hours, then the medium was replaced with one mixed with 1.0 mL of the test substance, and cultured for 48 hours. The cells were stained with Sirius Red and Fast Green, and collagen and protein were extracted by standard methods. The absorbance (570 nm) was measured to determine the amount of collagen per total protein. There were three samples in each case. 3-O-ethyl ascorbic acid was used as a positive control (data not shown). The results are shown in Table 3 below.
表3に示すように、シノリン単独(1μg)ではコラーゲンは生産されず(比較例64)、一方、シノリンと各抗酸化剤とを併用した場合には、各抗酸化剤単独の場合よりも吸光度が大きかった。したがって、シノリンと各抗酸化剤とを併用することによる相乗効果が確認された。 As shown in Table 3, no collagen was produced when shinorine was used alone (1 μg) (Comparative Example 64), whereas when shinorine was used in combination with each antioxidant, the absorbance was greater than when each antioxidant was used alone. Therefore, a synergistic effect was confirmed by using shinorine in combination with each antioxidant.
Claims (2)
(2) トラネキサム酸、コウジ酸、レチノール、アスコルビン酸、コエンザイムQ10、ハイドロキノン、トコフェロール及びβ-カロテンから成る群より選ばれる少なくとも1種の抗酸化剤と
を含む、コラーゲン産生促進剤。 (1) Shinorin and
(2) A collagen production promoter comprising at least one antioxidant selected from the group consisting of tranexamic acid, kojic acid, retinol, ascorbic acid, coenzyme Q10, hydroquinone, tocopherol and β-carotene.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019219007A JP7529959B2 (en) | 2019-12-03 | 2019-12-03 | Skin Composition |
JP2022118317A JP7504346B2 (en) | 2019-12-03 | 2022-07-25 | Skin Composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019219007A JP7529959B2 (en) | 2019-12-03 | 2019-12-03 | Skin Composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022118317A Division JP7504346B2 (en) | 2019-12-03 | 2022-07-25 | Skin Composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021088521A JP2021088521A (en) | 2021-06-10 |
JP7529959B2 true JP7529959B2 (en) | 2024-08-07 |
Family
ID=76219748
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019219007A Active JP7529959B2 (en) | 2019-12-03 | 2019-12-03 | Skin Composition |
JP2022118317A Active JP7504346B2 (en) | 2019-12-03 | 2022-07-25 | Skin Composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022118317A Active JP7504346B2 (en) | 2019-12-03 | 2022-07-25 | Skin Composition |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP7529959B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240358625A1 (en) * | 2021-08-12 | 2024-10-31 | Nagase & Co., Ltd. | Stabilization of mycosporine-like amino acids |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007262012A (en) | 2006-03-29 | 2007-10-11 | Pias Arise Kk | Hyaluronic acid production promoter, skin external preparation containing the hyaluronic acid production promoter, cosmetic, quasi drug, chapped skin ameliorating agent, and wrinkle ameliorating agent |
JP2011195534A (en) | 2010-03-23 | 2011-10-06 | Shiseido Co Ltd | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent |
WO2015174427A1 (en) | 2014-05-13 | 2015-11-19 | 学校法人北里研究所 | Method for producing mycosporine-like amino acid using microbes |
WO2017013441A1 (en) | 2015-07-23 | 2017-01-26 | King's College London | Compositions and methods using palythine |
JP2017197475A (en) | 2016-04-27 | 2017-11-02 | 長瀬産業株式会社 | Solution containing stabilized mycosporin-like amino acid, and method for producing the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3568979B2 (en) * | 1994-03-01 | 2004-09-22 | 御木本製薬株式会社 | Cosmetic for preventing sunburn and method for producing the same |
JPH10212225A (en) * | 1997-01-29 | 1998-08-11 | Sansho Seiyaku Co Ltd | Wrinkle preventive |
JP4088436B2 (en) * | 2001-11-15 | 2008-05-21 | ロート製薬株式会社 | Skin preparation |
JP2004315389A (en) * | 2003-04-14 | 2004-11-11 | Hakuto Co Ltd | External preparation for skin |
JP2005220084A (en) * | 2004-02-06 | 2005-08-18 | Kose Corp | Acerola seed extract-containing composition |
JP4973975B2 (en) * | 2005-07-11 | 2012-07-11 | 独立行政法人水産総合研究センター | Fibroblast growth promoter |
JP5913988B2 (en) * | 2012-01-06 | 2016-05-11 | 出光興産株式会社 | Multifunctional cosmetic ingredients containing Aureobasidium pullulans cell extract |
US9234204B2 (en) | 2012-08-07 | 2016-01-12 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
JP6049200B2 (en) * | 2013-05-17 | 2016-12-21 | マイクロアルジェコーポレーション株式会社 | Mycosporine-like amino acid and method for producing the same, UV protection agent, and antioxidant |
JP6272814B2 (en) * | 2015-11-06 | 2018-01-31 | 株式会社ドクターズチョイス | Hyaluronic acid production promoter |
JP6974952B2 (en) | 2016-04-28 | 2021-12-01 | ロート製薬株式会社 | External composition |
-
2019
- 2019-12-03 JP JP2019219007A patent/JP7529959B2/en active Active
-
2022
- 2022-07-25 JP JP2022118317A patent/JP7504346B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007262012A (en) | 2006-03-29 | 2007-10-11 | Pias Arise Kk | Hyaluronic acid production promoter, skin external preparation containing the hyaluronic acid production promoter, cosmetic, quasi drug, chapped skin ameliorating agent, and wrinkle ameliorating agent |
JP2011195534A (en) | 2010-03-23 | 2011-10-06 | Shiseido Co Ltd | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent |
WO2015174427A1 (en) | 2014-05-13 | 2015-11-19 | 学校法人北里研究所 | Method for producing mycosporine-like amino acid using microbes |
WO2017013441A1 (en) | 2015-07-23 | 2017-01-26 | King's College London | Compositions and methods using palythine |
JP2017197475A (en) | 2016-04-27 | 2017-11-02 | 長瀬産業株式会社 | Solution containing stabilized mycosporin-like amino acid, and method for producing the same |
Non-Patent Citations (2)
Title |
---|
Cosmetic Medicine in Japan 美容医学への扉、「皮膚のアンチエイジングと現在注目の機能性成分」、公開日:2007年1月、[online]、インターネットURL:http://cosmetic-medicine.jp/list/seibun.htm |
SOFW-Journal,Vol.129,2003年,p.2-5 |
Also Published As
Publication number | Publication date |
---|---|
JP2022136172A (en) | 2022-09-15 |
JP7504346B2 (en) | 2024-06-24 |
JP2021088521A (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210330691A1 (en) | Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats | |
CN111671716A (en) | Antioxidant skin color brightening composition and application thereof in cosmetics | |
KR20140082555A (en) | Compositions containing an extract of hydrangea macrophylla for. otaksa for skin whitening | |
JP2017214349A (en) | Cosmetic and Oral Composition | |
JP7504346B2 (en) | Skin Composition | |
KR101445642B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
KR20210144725A (en) | Anti-aging, antioxidant, anti-inflammatory and whitening agents, and cosmetics | |
TWI767168B (en) | Use of rosa plant extract for improving mitochondrial activity | |
KR102350857B1 (en) | Cosmetic composition containing lactic acid bacteria fermentation of chrysanthemum and magnolia extracted with YU SEONG hot spring water | |
JP2012232915A (en) | Skin care preparation for antiaging | |
CN112386547B (en) | Skin health care application of pineapple extract | |
JP2009298738A (en) | External preparation for skin | |
EP2902022A1 (en) | Vegfc production promoter | |
KR101775485B1 (en) | Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient | |
JP2000319122A (en) | Cell proliferation promoting cosmetic | |
JP2019199437A (en) | Skin external preparation | |
JP2009137878A (en) | Photo-aging inhibitor and skin preparation for external use containing the same | |
KR101398392B1 (en) | cosmetic compositions containing extract of Viburnum dilatatum Thunb used for antiwrinkle | |
JP7313755B1 (en) | Cosmetic raw material | |
JP2007131602A (en) | Bleaching external preparation | |
JP2007039397A (en) | Method for producing a composition having a collagen production promoting action from an alcoholic beverage fermented with brewer's yeast and the composition | |
KR102335682B1 (en) | Cosmetic Composition For Moisturizing Skin Comprising Fermentative Extract of Equisetum giganteum | |
KR100967805B1 (en) | Cosmetic composition for improving skin wrinkles containing shrimp tree leaf extract | |
JP2006273822A (en) | Cosmetic containing clear liquor (shochu) lees | |
JP2023054706A (en) | Skin beauty cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210901 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211223 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220725 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220725 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220816 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220902 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220905 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221111 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240507 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240704 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240704 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7529959 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |